FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047144788> ?p ?o ?g. }

• W3047144788 endingPage "2" @default.
• W3047144788 startingPage "1" @default.
• W3047144788 abstract "Nephroprotection has acknowledged ample development oflate and consists within the measures that defend the excretoryorgan against several aggressive factors. The thought ofnephroprotection in trendy drugs is comparatively new andmay hardly be derived before eighties. The advanced nature ofnephritic unwellnesss and their progression to renal disorder(both acute and chronic) and finish stage nephritic disease(ESRD) makes its management quite troublesome. The bulk ofcases of nephritic unwellness stay unnoticed unless they attainadvance stages once the traditional therapeutic interventionsare typically not decent to cure them fully. However the mostimportant drawback with uropathy is its progression to a stageonce just about no possibility works in the slightest degreeexcept the nephritic replacement medical care (RRT). 2 majorelements of RRT viz. qualitative analysis and excretory organtransplantation are extremely subtle and thereby too pricey tobe cheap for a median financial gain cluster. Solely tiny chunkof the elite category will take the posh of such a regime subjectto the supply of this facility in reach. That’s why most of thepatients of uropathy are left to die principally in developing andpoor countries attributable to non-availability of RRT facilitiesin their region or their inability to procure it. Globally, it's beencalculable that by a 2010 over 2 million people has been treatedby RRT at a value of $1 trillion. Quite one hundred countriesworldwide don't have any provision for RRT and consequently,quite 1,000,000 people will be assumed to die once a yearfrom ESRD. Concerning one hundred countries are known thatpossess no such facility in the slightest degree. Handiness ofkidneys for transplantation is another necessary drawback inline with RRT. Although, expenditure on RRT is cost accountingconcerning one trillion dollar however the substantialproportion of patients in would like of it, still remains untreatedand consequently has out-numbered those receiving thetreatment. In 1990 it had been three.78 million and is anticipatedto become seven.63 million in 2020. The dread increase withinthe prevalence of CKD that progresses to finish stage nephriticunwellness requiring nephritic replacement medical care,demands Brobdingnagian fund allocation, additionally, peoplewith excretory organ diseases square measure at associateincreasing risk of alternative general diseases which oftenproves to be fatal. In nut shell so it will be aforesaid that it'snearly next to not possible to supply replacement medical careto all or any patients requiring it. subsequent possibility leftwith the physicians is to consider alternatives and therefore thebest thanks to embark of such a scenario or a minimum of scaledown the prevalence and consequently the monetary burdento a major level, is to safeguard the excretory organ perform,slow the progression of unwellness and delay the requirementof RRT." @default.
• W3047144788 created "2020-08-10" @default.
• W3047144788 creator A5019916596 @default.
• W3047144788 date "2019-01-01" @default.
• W3047144788 modified "2023-09-23" @default.
• W3047144788 title "Scope of Natural Products in Combating Renal Disorders" @default.
• W3047144788 hasPublicationYear "2019" @default.
• W3047144788 type Work @default.
• W3047144788 sameAs 3047144788 @default.
• W3047144788 citedByCount "0" @default.
• W3047144788 crossrefType "journal-article" @default.
• W3047144788 hasAuthorship W3047144788A5019916596 @default.
• W3047144788 hasConcept C126322002 @default.
• W3047144788 hasConcept C159110408 @default.
• W3047144788 hasConcept C177713679 @default.
• W3047144788 hasConcept C27415008 @default.
• W3047144788 hasConcept C2777779818 @default.
• W3047144788 hasConcept C2779134260 @default.
• W3047144788 hasConcept C2779541074 @default.
• W3047144788 hasConcept C71924100 @default.
• W3047144788 hasConcept C77411442 @default.
• W3047144788 hasConceptScore W3047144788C126322002 @default.
• W3047144788 hasConceptScore W3047144788C159110408 @default.
• W3047144788 hasConceptScore W3047144788C177713679 @default.
• W3047144788 hasConceptScore W3047144788C27415008 @default.
• W3047144788 hasConceptScore W3047144788C2777779818 @default.
• W3047144788 hasConceptScore W3047144788C2779134260 @default.
• W3047144788 hasConceptScore W3047144788C2779541074 @default.
• W3047144788 hasConceptScore W3047144788C71924100 @default.
• W3047144788 hasConceptScore W3047144788C77411442 @default.
• W3047144788 hasIssue "1" @default.
• W3047144788 hasLocation W30471447881 @default.
• W3047144788 hasOpenAccess W3047144788 @default.
• W3047144788 hasPrimaryLocation W30471447881 @default.
• W3047144788 hasRelatedWork W1977275483 @default.
• W3047144788 hasRelatedWork W1979289586 @default.
• W3047144788 hasRelatedWork W1997127036 @default.
• W3047144788 hasRelatedWork W2005815757 @default.
• W3047144788 hasRelatedWork W2042875323 @default.
• W3047144788 hasRelatedWork W2060118730 @default.
• W3047144788 hasRelatedWork W2070705034 @default.
• W3047144788 hasRelatedWork W2084407133 @default.
• W3047144788 hasRelatedWork W2107148290 @default.
• W3047144788 hasRelatedWork W2118878823 @default.
• W3047144788 hasRelatedWork W2271060455 @default.
• W3047144788 hasRelatedWork W2401536783 @default.
• W3047144788 hasRelatedWork W2410640215 @default.
• W3047144788 hasRelatedWork W2411769421 @default.
• W3047144788 hasRelatedWork W2520277815 @default.
• W3047144788 hasRelatedWork W2620281190 @default.
• W3047144788 hasRelatedWork W2945090347 @default.
• W3047144788 hasRelatedWork W3083631011 @default.
• W3047144788 hasRelatedWork W3152395252 @default.
• W3047144788 hasRelatedWork W2188192537 @default.
• W3047144788 hasVolume "2" @default.
• W3047144788 isParatext "false" @default.
• W3047144788 isRetracted "false" @default.
• W3047144788 magId "3047144788" @default.
• W3047144788 workType "article" @default.